<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xsi:schemaLocation="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" returnVersion="2020v4.1">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2022-04-25T15:59:41-05:00</ReturnTs>
    <TaxPeriodEndDt>2021-06-30</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmName>
        <BusinessNameLine1Txt>BDO USA LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>9500 Bryn Mawr Ave Suite 300</AddressLine1Txt>
        <CityNm>Rosemont</CityNm>
        <StateAbbreviationCd>IL</StateAbbreviationCd>
        <ZIPCd>60018</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2020-07-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>841558631</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>Pulmonary Fibrosis Foundation</BusinessNameLine1Txt>
      </BusinessName>
      <InCareOfNm>% SCOTT STASZAK COO</InCareOfNm>
      <BusinessNameControlTxt>PULM</BusinessNameControlTxt>
      <PhoneNum>3122652182</PhoneNum>
      <USAddress>
        <AddressLine1Txt>230 East Ohio Street Suite 500</AddressLine1Txt>
        <CityNm>Chicago</CityNm>
        <StateAbbreviationCd>IL</StateAbbreviationCd>
        <ZIPCd>606113270</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>Scott Staszak</PersonNm>
      <PersonTitleTxt>COO</PersonTitleTxt>
      <PhoneNum>3125879272</PhoneNum>
      <SignatureDt>2022-04-20</SignatureDt>
      <DiscussWithPaidPreparerInd>true</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>Scott</PersonFirstNm>
        <PersonLastNm>Staszak</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>JACOB COOK</PreparerPersonNm>
      <PTIN>P01240455</PTIN>
      <PhoneNum>8476762000</PhoneNum>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>2</TrustedCustomerCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2020</TaxYr>
    <BuildTS>2022-09-23 18:48:47Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="10">
    <IRS990 documentId="IRS990" referenceDocumentId="IRS990ScheduleO">
      <PrincipalOfficerNm>Scott Staszak</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>230 E Ohio Street Suite 500</AddressLine1Txt>
        <CityNm>Chicago</CityNm>
        <StateAbbreviationCd>IL</StateAbbreviationCd>
        <ZIPCd>606113270</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>10094902</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>false</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>www.pulmonaryfibrosis.org</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>2000</FormationYr>
      <LegalDomicileStateCd>CO</LegalDomicileStateCd>
      <ActivityOrMissionDesc>To mobilize people and resources to provide access to high-quality care and lead research for a cure so that people with pulmonary fibrosis will live longer, healthier lives.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>15</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>15</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>39</TotalEmployeeCnt>
      <TotalVolunteersCnt>1899</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>8450064</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>6636670</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>2548146</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>2908697</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>293084</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>65617</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>-589250</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>-645389</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>10702044</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>8965595</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>342863</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>302895</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>3557722</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>3807101</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>1046077</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>7391038</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>4231849</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>11291623</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>8341845</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>-589579</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>623750</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>10892804</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>14745592</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>3594974</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>5433309</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>7297830</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>9312283</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>TO MOBILIZE PEOPLE AND RESOURCES TO PROVIDE ACCESS TO HIGH-QUALITY CARE AND LEAD RESEARCH FOR A CURE SO THAT PEOPLE WITH PULMONARY FIBROSIS WILL LIVE LONGER, HEALTHIER LIVES.</MissionDesc>
      <SignificantNewProgramSrvcInd>false</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>false</SignificantChangeInd>
      <ExpenseAmt>2095135</ExpenseAmt>
      <GrantAmt>0</GrantAmt>
      <RevenueAmt>2214951</RevenueAmt>
      <Desc>PFF PATIENT REGISTRY: TOTAL REVENUE RECOGNIZED FOR THE PROGRAM WAS $2,910,419 WHICH INCLUDED CONTRIBUTIONS AND SPONSORSHIPS OF $695,468 IN ADDITION TO THE PROGRAM SERVICE REVENUE OF $2,214,951. THE PFF REGISTRY (REGISTRY) IS A RESEARCH EFFORT THAT BRINGS TOGETHER MULTIPLE STAKEHOLDERS INCLUDING PATIENTS, HEALTH CARE PROVIDERS, AND RESEARCHERS TO ADVANCE RESEARCH AND IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH PULMONARY FIBROSIS (PF). THE CRUX OF THE REGISTRY IS COMPRISED OF AN ELECTRONIC DATABASE OF PATIENT INFORMATION ON DIAGNOSIS, TREATMENT, AND QUALITY OF LIFE THAT IS DE-IDENTIFIED (MADE ANONYMOUS) AND (CONTINUED ON SCHEDULE O)</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>1211362</ExpenseAmt>
        <GrantAmt>0</GrantAmt>
        <RevenueAmt>0</RevenueAmt>
        <Desc>EDUCATION: TOTAL REVENUE RECOGNIZED FOR EDUCATION WAS $782,495 WHICH INCLUDED $208,539 IN CONTRIBUTIONS AND SPONSORSHIPS RECEIVED DURING THE YEAR OR RELEASED FROM PRIOR YEAR RECEIPTS. THE PULMONARY FIBROSIS FOUNDATION (PFF) IS COMMITTED TO PROVIDING QUALITY DISEASE EDUCATION TO THE PULMONARY FIBROSIS COMMUNITY. THE PFF STRIVES TO PROVIDE PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTH CARE PROVIDERS WITH THE RESOURCES NECESSARY TO MORE FULLY UNDERSTAND PF, AND TO PROVIDE PATIENTS WITH THE TOOLS NECESSARY TO LIVE WITH THE DISEASE AND IMPROVE THEIR QUALITY OF LIFE. (CONTINUED ON SCHEDULE O)</Desc>
      </ProgSrvcAccomActy2Grp>
      <ProgSrvcAccomActy3Grp>
        <ExpenseAmt>621082</ExpenseAmt>
        <GrantAmt>0</GrantAmt>
        <RevenueAmt>0</RevenueAmt>
        <Desc>PROGRAM SUPPORT: TOTAL REVENUE RECOGNIZED FOR THE PROGRAM SUPPORT WAS $175,000 WHICH INCLUDED $15,129 IN CONTRIBUTIONS AND SPONSORSHIPS RECEIVED DURING THE YEAR OR RELEASED FROM PRIOR YEAR RECEIPTS. WE BEGAN THE FISCAL YEAR BY DEVELOPING A NEW BRAND IDENTITY FOR THE PFF. THE NEW LOGO MARK IS ATTENTION-GETTING, EASY TO UNDERSTAND, AND MEMORABLE. IT IS BASED ON TWO HUMAN LUNGS AND PROMOTES MODERNITY, POSITIVITY, AND FORWARD-THINKING. IN NOVEMBER, WE RELAUNCHED OUR PUBLIC AWARENESS CAMPAIGN WITH A NEW THEME AND LOGO ENTITLED "PINPOINT PF" TO ENCOURAGE AT-RISK PATIENTS, CAREGIVERS, (CONTINUED ON SCHEDULE O)</Desc>
      </ProgSrvcAccomActy3Grp>
      <TotalOtherProgSrvcExpenseAmt>2061192</TotalOtherProgSrvcExpenseAmt>
      <TotalOtherProgSrvcGrantAmt>302895</TotalOtherProgSrvcGrantAmt>
      <TotalOtherProgSrvcRevenueAmt>693746</TotalOtherProgSrvcRevenueAmt>
      <TotalProgramServiceExpensesAmt>5988771</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="IRS990ScheduleA">true</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="IRS990ScheduleB">true</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd referenceDocumentId="IRS990ScheduleC">false</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd referenceDocumentId="IRS990ScheduleC">true</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd referenceDocumentId="IRS990ScheduleC">false</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="IRS990ScheduleD">false</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="IRS990ScheduleD">false</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="IRS990ScheduleD">false</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="IRS990ScheduleD">false</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd referenceDocumentId="IRS990ScheduleD">false</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="IRS990ScheduleD">true</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="IRS990ScheduleD">false</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="IRS990ScheduleD">false</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="IRS990ScheduleD">false</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="IRS990ScheduleD">false</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="IRS990ScheduleD">true</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">true</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">false</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>false</SchoolOperatingInd>
      <ForeignOfficeInd>false</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="IRS990ScheduleF">false</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="IRS990ScheduleF">true</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="IRS990ScheduleF">false</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd referenceDocumentId="IRS990ScheduleG">false</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd referenceDocumentId="IRS990ScheduleG">true</FundraisingActivitiesInd>
      <GamingActivitiesInd referenceDocumentId="IRS990ScheduleG">false</GamingActivitiesInd>
      <OperateHospitalInd>false</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="IRS990ScheduleI">true</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="IRS990ScheduleI">false</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="IRS990ScheduleJ">true</ScheduleJRequiredInd>
      <TaxExemptBondsInd>false</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>false</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>false</PYExcessBenefitTransInd>
      <LoanOutstandingInd>false</LoanOutstandingInd>
      <GrantToRelatedPersonInd>false</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>false</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>false</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>false</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd>false</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>false</DeductibleArtContributionInd>
      <TerminateOperationsInd>false</TerminateOperationsInd>
      <PartialLiquidationInd>false</PartialLiquidationInd>
      <DisregardedEntityInd>false</DisregardedEntityInd>
      <RelatedEntityInd>false</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>false</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>false</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>false</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>true</ScheduleORequiredInd>
      <IRPDocumentCnt>27</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>true</BackupWthldComplianceInd>
      <EmployeeCnt>39</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>true</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>false</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>false</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>false</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>false</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>false</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>true</QuidProQuoContributionsInd>
      <QuidProQuoContriDisclInd>true</QuidProQuoContriDisclInd>
      <Form8282PropertyDisposedOfInd>false</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>false</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>false</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>false</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>false</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>false</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>15</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>15</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>false</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>false</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>false</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>false</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>false</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>false</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>false</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>true</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>true</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>false</OfficerMailingAddressInd>
      <LocalChaptersInd>false</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>true</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>true</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>true</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>true</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>true</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>true</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>true</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>true</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>false</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>DC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>FL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>GA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ME</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ND</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>RI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <PersonNm>SCOTT STASZAK COO</PersonNm>
        <PhoneNum>3122652182</PhoneNum>
        <USAddress>
          <AddressLine1Txt>230 EAST OHIO STREET SUITE 500</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60611</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>William T Schmidt</PersonNm>
        <TitleTxt>Director/President and CEO</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>282100</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>28500</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Scott Staszak</PersonNm>
        <TitleTxt>Chief Operating Officer</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>212987</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>26000</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Laura Sadler</PersonNm>
        <TitleTxt>Chief Marketing Officer</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>186056</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>6794</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Seth Klein</PersonNm>
        <TitleTxt>SENIOR VP, DEVELOPMENT</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>153934</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>12781</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Kathryn TREBONSKY</PersonNm>
        <TitleTxt>VP, FINANCE THRU 04/01/21</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>135889</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>26648</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Zoe Bubany</PersonNm>
        <TitleTxt>VP, Board &amp; External Relations</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>121221</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>10379</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>George Eliades</PersonNm>
        <TitleTxt>Chairman</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>David McNinch</PersonNm>
        <TitleTxt>Vice-Chair</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Laurie Chandler CFP</PersonNm>
        <TitleTxt>Treasurer</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Terence Hales</PersonNm>
        <TitleTxt>Secretary</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Martin Attwell</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Dana A Ball</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Julie Halston</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Jeff Harris</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Mike Henderson</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Susan Jacobs</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PJ Kamani</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Andy Limper</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Barbara Murphy</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Patricia Rosa</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Bill Schmidt</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>1092187</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>111102</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>6</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>false</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>true</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>false</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>LC Williams Associates</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>150 N Michigan Ave Ste 3800</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60601</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Public Relations</ServicesDesc>
        <CompensationAmt>429175</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>Dorothy Coyle Raclaw</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>5855 N Kenneth Ave</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60646</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Marketing Consulting</ServicesDesc>
        <CompensationAmt>136825</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>HCM Strategies LLC</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>1156 15th Street NW Ste 850</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Advocacy Consulting</ServicesDesc>
        <CompensationAmt>130000</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>3</CntrctRcvdGreaterThan100KCnt>
      <FundraisingAmt>1038876</FundraisingAmt>
      <GovernmentGrantsAmt>560300</GovernmentGrantsAmt>
      <AllOtherContributionsAmt>5037494</AllOtherContributionsAmt>
      <NoncashContributionsAmt>6721</NoncashContributionsAmt>
      <TotalContributionsAmt>6636670</TotalContributionsAmt>
      <ProgramServiceRevenueGrp>
        <Desc>PFF PATIENT REGISTRY</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>2214951</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>2214951</RelatedOrExemptFuncIncomeAmt>
      </ProgramServiceRevenueGrp>
      <ProgramServiceRevenueGrp>
        <Desc>CORP PARTNERSHIPS</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>693746</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>693746</RelatedOrExemptFuncIncomeAmt>
      </ProgramServiceRevenueGrp>
      <TotalProgramServiceRevenueAmt>2908697</TotalProgramServiceRevenueAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>152919</TotalRevenueColumnAmt>
        <ExclusionAmt>152919</ExclusionAmt>
      </InvestmentIncomeGrp>
      <IncmFromInvestBondProceedsGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </IncmFromInvestBondProceedsGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </RoyaltiesRevenueGrp>
      <RentalIncomeOrLossGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </RentalIncomeOrLossGrp>
      <NetRentalIncomeOrLossGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetRentalIncomeOrLossGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>372816</SecuritiesAmt>
        <OtherAmt>151</OtherAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>434797</SecuritiesAmt>
        <OtherAmt>25472</OtherAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>-61981</SecuritiesAmt>
        <OtherAmt>-25321</OtherAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>-87302</TotalRevenueColumnAmt>
        <ExclusionAmt>-87302</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <FundraisingGrossIncomeAmt>0</FundraisingGrossIncomeAmt>
      <ContriRptFundraisingEventAmt>1038876</ContriRptFundraisingEventAmt>
      <FundraisingDirectExpensesAmt>538529</FundraisingDirectExpensesAmt>
      <NetIncmFromFundraisingEvtGrp>
        <TotalRevenueColumnAmt>-538529</TotalRevenueColumnAmt>
        <ExclusionAmt>-538529</ExclusionAmt>
      </NetIncmFromFundraisingEvtGrp>
      <GamingGrossIncomeAmt>0</GamingGrossIncomeAmt>
      <GamingDirectExpensesAmt>0</GamingDirectExpensesAmt>
      <NetIncomeFromGamingGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetIncomeFromGamingGrp>
      <GrossSalesOfInventoryAmt>10784</GrossSalesOfInventoryAmt>
      <CostOfGoodsSoldAmt>130509</CostOfGoodsSoldAmt>
      <NetIncomeOrLossGrp>
        <TotalRevenueColumnAmt>-119725</TotalRevenueColumnAmt>
        <ExclusionAmt>-119725</ExclusionAmt>
      </NetIncomeOrLossGrp>
      <OtherRevenueMiscGrp>
        <Desc>UBIT REFUND</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>11461</TotalRevenueColumnAmt>
        <ExclusionAmt>11461</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueMiscGrp>
        <Desc>INTEREST REFUND</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>1404</TotalRevenueColumnAmt>
        <ExclusionAmt>1404</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueTotalAmt>12865</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>8965595</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>2908697</RelatedOrExemptFuncIncomeAmt>
        <ExclusionAmt>-579772</ExclusionAmt>
      </TotalRevenueGrp>
      <InfoInScheduleOPartIXInd>X</InfoInScheduleOPartIXInd>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>302895</TotalAmt>
        <ProgramServicesAmt>302895</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <GrantsToDomesticIndividualsGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </GrantsToDomesticIndividualsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <BenefitsToMembersGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </BenefitsToMembersGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>909868</TotalAmt>
        <ProgramServicesAmt>556639</ProgramServicesAmt>
        <ManagementAndGeneralAmt>85478</ManagementAndGeneralAmt>
        <FundraisingAmt>267751</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <CompDisqualPersonsGrp>
        <TotalAmt>0</TotalAmt>
      </CompDisqualPersonsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>2464251</TotalAmt>
        <ProgramServicesAmt>1315096</ProgramServicesAmt>
        <ManagementAndGeneralAmt>697316</ManagementAndGeneralAmt>
        <FundraisingAmt>451839</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>65623</TotalAmt>
        <ProgramServicesAmt>37239</ProgramServicesAmt>
        <ManagementAndGeneralAmt>15697</ManagementAndGeneralAmt>
        <FundraisingAmt>12687</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>185817</TotalAmt>
        <ProgramServicesAmt>74338</ProgramServicesAmt>
        <ManagementAndGeneralAmt>76893</ManagementAndGeneralAmt>
        <FundraisingAmt>34586</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>181542</TotalAmt>
        <ProgramServicesAmt>105861</ProgramServicesAmt>
        <ManagementAndGeneralAmt>39525</ManagementAndGeneralAmt>
        <FundraisingAmt>36156</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesManagementGrp>
        <TotalAmt>0</TotalAmt>
      </FeesForServicesManagementGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>59068</TotalAmt>
        <ManagementAndGeneralAmt>59068</ManagementAndGeneralAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>31327</TotalAmt>
        <ManagementAndGeneralAmt>31327</ManagementAndGeneralAmt>
      </FeesForServicesAccountingGrp>
      <FeesForServicesLobbyingGrp>
        <TotalAmt>198656</TotalAmt>
        <ProgramServicesAmt>198656</ProgramServicesAmt>
      </FeesForServicesLobbyingGrp>
      <FeesForServicesProfFundraising>
        <TotalAmt>0</TotalAmt>
      </FeesForServicesProfFundraising>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>23202</TotalAmt>
        <ManagementAndGeneralAmt>23202</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>2920015</TotalAmt>
        <ProgramServicesAmt>2688092</ProgramServicesAmt>
        <ManagementAndGeneralAmt>172597</ManagementAndGeneralAmt>
        <FundraisingAmt>59326</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>117996</TotalAmt>
        <ProgramServicesAmt>117996</ProgramServicesAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>227012</TotalAmt>
        <ProgramServicesAmt>150087</ProgramServicesAmt>
        <ManagementAndGeneralAmt>15241</ManagementAndGeneralAmt>
        <FundraisingAmt>61684</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>12660</TotalAmt>
        <ProgramServicesAmt>7475</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2539</ManagementAndGeneralAmt>
        <FundraisingAmt>2646</FundraisingAmt>
      </InformationTechnologyGrp>
      <RoyaltiesGrp>
        <TotalAmt>0</TotalAmt>
      </RoyaltiesGrp>
      <OccupancyGrp>
        <TotalAmt>223064</TotalAmt>
        <ProgramServicesAmt>130881</ProgramServicesAmt>
        <ManagementAndGeneralAmt>45851</ManagementAndGeneralAmt>
        <FundraisingAmt>46332</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>5926</TotalAmt>
        <ProgramServicesAmt>2196</ProgramServicesAmt>
        <ManagementAndGeneralAmt>3633</ManagementAndGeneralAmt>
        <FundraisingAmt>97</FundraisingAmt>
      </TravelGrp>
      <PymtTravelEntrtnmntPubOfclGrp>
        <TotalAmt>0</TotalAmt>
      </PymtTravelEntrtnmntPubOfclGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>4510</TotalAmt>
        <ProgramServicesAmt>2681</ProgramServicesAmt>
        <ManagementAndGeneralAmt>896</ManagementAndGeneralAmt>
        <FundraisingAmt>933</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <InterestGrp>
        <TotalAmt>0</TotalAmt>
      </InterestGrp>
      <PaymentsToAffiliatesGrp>
        <TotalAmt>0</TotalAmt>
      </PaymentsToAffiliatesGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>61587</TotalAmt>
        <ProgramServicesAmt>48438</ProgramServicesAmt>
        <ManagementAndGeneralAmt>6439</ManagementAndGeneralAmt>
        <FundraisingAmt>6710</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>36244</TotalAmt>
        <ProgramServicesAmt>20469</ProgramServicesAmt>
        <ManagementAndGeneralAmt>8529</ManagementAndGeneralAmt>
        <FundraisingAmt>7246</FundraisingAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>EVENT EXPENSE - AUDIO VISUAL</Desc>
        <TotalAmt>97911</TotalAmt>
        <ProgramServicesAmt>96654</ProgramServicesAmt>
        <ManagementAndGeneralAmt>257</ManagementAndGeneralAmt>
        <FundraisingAmt>1000</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>SOFTWARE SUBSCRIPTIONS - SAAS</Desc>
        <TotalAmt>89269</TotalAmt>
        <ProgramServicesAmt>60234</ProgramServicesAmt>
        <ManagementAndGeneralAmt>414</ManagementAndGeneralAmt>
        <FundraisingAmt>28621</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>ALLOCATED SOFTWARE SUBS</Desc>
        <TotalAmt>75006</TotalAmt>
        <ProgramServicesAmt>44900</ProgramServicesAmt>
        <ManagementAndGeneralAmt>10490</ManagementAndGeneralAmt>
        <FundraisingAmt>19616</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>DUES/SUBSCRIPTIONS/REGISTRAT</Desc>
        <TotalAmt>33602</TotalAmt>
        <ProgramServicesAmt>22422</ProgramServicesAmt>
        <ManagementAndGeneralAmt>9411</ManagementAndGeneralAmt>
        <FundraisingAmt>1769</FundraisingAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>14794</TotalAmt>
        <ProgramServicesAmt>5522</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2194</ManagementAndGeneralAmt>
        <FundraisingAmt>7078</FundraisingAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>8341845</TotalAmt>
        <ProgramServicesAmt>5988771</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1306997</ManagementAndGeneralAmt>
        <FundraisingAmt>1046077</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>483720</BOYAmt>
        <EOYAmt>537465</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>4670786</BOYAmt>
        <EOYAmt>5853121</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>55718</BOYAmt>
        <EOYAmt>58296</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <BOYAmt>33997</BOYAmt>
        <EOYAmt>1503472</EOYAmt>
      </AccountsReceivableGrp>
      <ReceivablesFromOfficersEtcGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </ReceivablesFromOfficersEtcGrp>
      <RcvblFromDisqualifiedPrsnGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RcvblFromDisqualifiedPrsnGrp>
      <OthNotesLoansReceivableNetGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OthNotesLoansReceivableNetGrp>
      <InventoriesForSaleOrUseGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InventoriesForSaleOrUseGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>137343</BOYAmt>
        <EOYAmt>507279</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>221720</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>176349</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>42990</BOYAmt>
        <EOYAmt>45371</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>4863723</BOYAmt>
        <EOYAmt>5549485</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <InvestmentsOtherSecuritiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InvestmentsOtherSecuritiesGrp>
      <InvestmentsProgramRelatedGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InvestmentsProgramRelatedGrp>
      <IntangibleAssetsGrp>
        <BOYAmt>172896</BOYAmt>
        <EOYAmt>259472</EOYAmt>
      </IntangibleAssetsGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>431631</BOYAmt>
        <EOYAmt>431631</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>10892804</BOYAmt>
        <EOYAmt>14745592</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>1523757</BOYAmt>
        <EOYAmt>2077344</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>300000</BOYAmt>
        <EOYAmt>337500</EOYAmt>
      </GrantsPayableGrp>
      <DeferredRevenueGrp>
        <BOYAmt>1207629</BOYAmt>
        <EOYAmt>2437790</EOYAmt>
      </DeferredRevenueGrp>
      <TaxExemptBondLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </TaxExemptBondLiabilitiesGrp>
      <EscrowAccountLiabilityGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </EscrowAccountLiabilityGrp>
      <LoansFromOfficersDirectorsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </LoansFromOfficersDirectorsGrp>
      <MortgNotesPyblScrdInvstPropGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </MortgNotesPyblScrdInvstPropGrp>
      <UnsecuredNotesLoansPayableGrp>
        <BOYAmt>560300</BOYAmt>
        <EOYAmt>580675</EOYAmt>
      </UnsecuredNotesLoansPayableGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>3288</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>3594974</BOYAmt>
        <EOYAmt>5433309</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>4012393</BOYAmt>
        <EOYAmt>6584930</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>3285437</BOYAmt>
        <EOYAmt>2727353</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>7297830</BOYAmt>
        <EOYAmt>9312283</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>10892804</BOYAmt>
        <EOYAmt>14745592</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>623750</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>640807</NetUnrlzdGainsLossesInvstAmt>
      <PriorPeriodAdjustmentsAmt>749896</PriorPeriodAdjustmentsAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>false</AccountantCompileOrReviewInd>
      <FSAuditedInd>true</FSAuditedInd>
      <FSAuditedBasisGrp>
        <SeparateBasisFinclStmtInd>X</SeparateBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>true</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>false</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="IRS990ScheduleA">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>5775504</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5989047</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>8449631</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>8450064</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>6636670</CurrentTaxYearAmt>
        <TotalAmt>35300916</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TaxRevLeviedOrgnztnlBnft170Grp>
        <TotalAmt>0</TotalAmt>
      </TaxRevLeviedOrgnztnlBnft170Grp>
      <GovtFurnSrvcFcltsVl170Grp>
        <TotalAmt>0</TotalAmt>
      </GovtFurnSrvcFcltsVl170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>5775504</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5989047</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>8449631</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>8450064</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>6636670</CurrentTaxYearAmt>
        <TotalAmt>35300916</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>13670470</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>21630446</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>11635</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>69969</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>273967</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>257033</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>152919</CurrentTaxYearAmt>
        <TotalAmt>765523</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <UnrelatedBusinessNetIncm170Grp>
        <TotalAmt>0</TotalAmt>
      </UnrelatedBusinessNetIncm170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>1060</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>691</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>234</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>2</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>12865</CurrentTaxYearAmt>
        <TotalAmt>14852</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>36081291</TotalSupportAmt>
      <GrossReceiptsRltdActivitiesAmt>13473417</GrossReceiptsRltdActivitiesAmt>
      <PublicSupportCY170Pct>0.59949</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.56411</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="IRS990ScheduleB">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleC documentId="IRS990ScheduleC">
      <TotalGrassrootsLobbyingGrp>
        <FilingOrganizationsTotalAmt>37091</FilingOrganizationsTotalAmt>
      </TotalGrassrootsLobbyingGrp>
      <TotalDirectLobbyingGrp>
        <FilingOrganizationsTotalAmt>161564</FilingOrganizationsTotalAmt>
      </TotalDirectLobbyingGrp>
      <TotalLobbyingExpendGrp>
        <FilingOrganizationsTotalAmt>198655</FilingOrganizationsTotalAmt>
      </TotalLobbyingExpendGrp>
      <OtherExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>5790116</FilingOrganizationsTotalAmt>
      </OtherExemptPurposeExpendGrp>
      <TotalExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>5988771</FilingOrganizationsTotalAmt>
      </TotalExemptPurposeExpendGrp>
      <LobbyingNontaxableAmountGrp>
        <FilingOrganizationsTotalAmt>449439</FilingOrganizationsTotalAmt>
      </LobbyingNontaxableAmountGrp>
      <GrassrootsNontaxableGrp>
        <FilingOrganizationsTotalAmt>112360</FilingOrganizationsTotalAmt>
      </GrassrootsNontaxableGrp>
      <TotLbbyngGrassrootMnsNonTxGrp />
      <TotLbbyExpendMnsLbbyngNonTxGrp />
      <AvgLobbyingNontaxableAmountGrp>
        <CurrentYearMinus3Amt>456061</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>466993</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>602580</CurrentYearMinus1Amt>
        <CurrentYearAmt>449439</CurrentYearAmt>
        <TotalAmt>1975073</TotalAmt>
      </AvgLobbyingNontaxableAmountGrp>
      <LobbyingCeilingAmt>2962610</LobbyingCeilingAmt>
      <AvgTotalLobbyingExpendGrp>
        <CurrentYearMinus3Amt>21008</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>79435</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>280017</CurrentYearMinus1Amt>
        <CurrentYearAmt>198655</CurrentYearAmt>
        <TotalAmt>579115</TotalAmt>
      </AvgTotalLobbyingExpendGrp>
      <AvgGrassrootsNontaxableGrp>
        <CurrentYearMinus3Amt>114015</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>116748</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>150645</CurrentYearMinus1Amt>
        <CurrentYearAmt>112360</CurrentYearAmt>
        <TotalAmt>493768</TotalAmt>
      </AvgGrassrootsNontaxableGrp>
      <GrassrootsCeilingAmt>740652</GrassrootsCeilingAmt>
      <AvgGrassrootsLobbyingExpendGrp>
        <CurrentYearMinus2Amt>58081</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>40551</CurrentYearMinus1Amt>
        <CurrentYearAmt>37091</CurrentYearAmt>
        <TotalAmt>135723</TotalAmt>
      </AvgGrassrootsLobbyingExpendGrp>
    </IRS990ScheduleC>
    <IRS990ScheduleD documentId="IRS990ScheduleD">
      <ArtPublicExhibitionAmountsGrp />
      <HeldWorksArtGrp />
      <CYMinus3YrEndwmtFundGrp />
      <CYMinus4YrEndwmtFundGrp />
      <LandGrp />
      <BuildingsGrp />
      <LeaseholdImprovementsGrp />
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>151380</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>109367</DepreciationAmt>
        <BookValueAmt>42013</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp>
        <OtherCostOrOtherBasisAmt>70340</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>66982</DepreciationAmt>
        <BookValueAmt>3358</BookValueAmt>
      </OtherLandBuildingsGrp>
      <TotalBookValueLandBuildingsAmt>45371</TotalBookValueLandBuildingsAmt>
      <FederalIncomeTaxLiabilityAmt>0</FederalIncomeTaxLiabilityAmt>
      <TotalLiabilityAmt>0</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>10275440</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>640807</NetUnrealizedGainsInvstAmt>
      <OtherRevenueAmt>669038</OtherRevenueAmt>
      <RevenueNotReportedAmt>1309845</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>8965595</RevenueSubtotalAmt>
      <TotalRevenuePerForm990Amt>8965595</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>9010883</TotExpnsEtcAuditedFinclStmtAmt>
      <OtherExpensesIncludedAmt>669038</OtherExpensesIncludedAmt>
      <ExpensesNotReportedAmt>669038</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>8341845</ExpensesSubtotalAmt>
      <TotalExpensesPerForm990Amt>8341845</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE D, PART X, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("IRC"), EXCEPT FOR NET INCOME DERIVED FROM UNRELATED BUSINESS ACTIVITIES. IN ADDITION, THE ORGANIZATION QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER SECTION 170(B)(1)(A) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION OTHER THAN A PRIVATE FOUNDATION UNDER IRC SECTION 509(A). THE ORGANIZATION'S INCOME TAX FILINGS ARE SUBJECT TO AUDIT BY VARIOUS TAXING AUTHORITIES. IN EVALUATING THE ORGANIZATION'S ACTIVITIES, MANAGEMENT BELIEVES ITS POSITION OF TAX-EXEMPT STATUS IS BASED ON CURRENT FACTS AND CIRCUMSTANCES AND THERE HAVE BEEN NO UNCERTAIN POSITIONS TAKEN RELATED TO RECORDING INCOME TAXES. IT IS THE POLICY OF THE ORGANIZATION TO INCLUDE IN MANAGEMENT AND GENERAL EXPENSES PENALTIES AND INTEREST ASSESSED BY INCOME TAXING AUTHORITIES. THERE WERE NO PENALTIES FROM TAXING AUTHORITIES INCLUDED IN MANAGEMENT AND GENERAL EXPENSES FOR THE YEAR ENDED JUNE 30, 2021.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule D, Part XI, Line 4b - Other Adjustments</FormAndLineReferenceDesc>
        <ExplanationTxt>Special Events: $(538,529) Sale of Goods: $(130,509) Total: $(669,038)</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule D, Part XII, Line 2d - Other Adjustments</FormAndLineReferenceDesc>
        <ExplanationTxt>Special Events: $538,529 Sale of Goods: $130,509 Total: $669,038</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="IRS990ScheduleF">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>50000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>0</SubtotalEmployeesCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <SubtotalSpentAmt>50000</SubtotalSpentAmt>
      <TotalSpentAmt>50000</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>See Part IV</PurposeOfGrantTxt>
        <CashGrantAmt>50000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>Wire</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>1</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>false</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>false</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>false</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>false</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>false</ForeignPartnershipInd>
      <BoycottCountriesInd>false</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Part I, Line 2</FormAndLineReferenceDesc>
        <ExplanationTxt>For larger grants, the Organization requests semi-annual reports detailing the use of grant funds from the recipient organizations.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Part II, Line 1, COLUMN (D)</FormAndLineReferenceDesc>
        <ExplanationTxt>1. TEL AVIV SOURASKY MEDICAL CENTER - PROJECT TITLE - SINGLE-CELL IMMUNOPHENOTYPING OF CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES PULMONARY FIBROSIS (PF) IS A CHRONIC LUNG DISEASE THAT OCCURS WHEN LUNG TISSUE BECOMES DAMAGED AND SCARRED, MAKING BREATHING DIFFICULT. THERE ARE MANY TYPES OF PF WITH DIFFERENT CAUSES AND SEVERITY LEVELS. DETERMINING THE CORRECT DIAGNOSIS IS IMPORTANT FOR RISK ASSESSMENT AND TREATMENT DECISIONS; HOWEVER, IT MAY NECESSITATE A LUNG BIOPSY WHICH MAY BE RISKY. IN THIS RESEARCH PROJECT WE WILL USE A HIGHLY INNOVATIVE TECHNOLOGY CALLED "SINGLE-CELL PROFILING" WHICH ALLOWS THE RESEARCHERS TO LOOK AT CELLS, THE BUILDING BLOCKS OF OUR BODY, AT A HIGHER RESOLUTION THAN EVER BEFORE. WE WILL USE IT TO IDENTIFY SPECIFIC CHANGES IN THE IMMUNE SYSTEM IN THE BLOOD THAT REFLECT THE SPECIFIC CAUSE OF FIBROSIS IN THE LUNGS. SOME OF THESE CHANGES COULD LATER BE USED AS BIOMARKERS TO BETTER DIAGNOSE THE CAUSE OF PF, WITHOUT THE NEED FOR A LUNG BIOPSY. INSIGHTS FROM THIS RESEARCH WILL LEAD TO A BETTER UNDERSTANDING OF THE IMMUNE SYSTEM'S ROLE IN PF, FACILITATING THE DEVELOPMENT OF NEW TREATMENTS THAT ARE TAILORED TO THE SPECIFIC CAUSE OF PF IN AN INDIVIDUAL PATIENT.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleG documentId="IRS990ScheduleG">
      <FundraisingEventInformationGrp>
        <Event1Nm>PFF WALKS</Event1Nm>
        <GrossReceiptsEvent1Amt>684791</GrossReceiptsEvent1Amt>
        <CharitableContriEvent1Amt>684791</CharitableContriEvent1Amt>
        <OtherDirectExpensesEvent1Amt>341175</OtherDirectExpensesEvent1Amt>
        <Event2Nm>BROADWAY BELTS</Event2Nm>
        <GrossReceiptsEvent2Amt>354085</GrossReceiptsEvent2Amt>
        <CharitableContriEvent2Amt>354085</CharitableContriEvent2Amt>
        <RentFacilityCostsEvent2Amt>500</RentFacilityCostsEvent2Amt>
        <FoodAndBeverageEvent2Amt>3911</FoodAndBeverageEvent2Amt>
        <EntertainmentEvent2Amt>52</EntertainmentEvent2Amt>
        <OtherDirectExpensesEvent2Amt>192891</OtherDirectExpensesEvent2Amt>
        <OtherEventsTotalCnt>0</OtherEventsTotalCnt>
        <GrossReceiptsTotalAmt>1038876</GrossReceiptsTotalAmt>
        <CharitableContributionsTotAmt>1038876</CharitableContributionsTotAmt>
        <RentFcltyCostsTotalEventsAmt>500</RentFcltyCostsTotalEventsAmt>
        <FoodAndBeverageTotalEventsAmt>3911</FoodAndBeverageTotalEventsAmt>
        <EntertainmentTotalEventsAmt>52</EntertainmentTotalEventsAmt>
        <OthDirectExpnssTotalEventsAmt>534066</OthDirectExpnssTotalEventsAmt>
        <DirectExpenseSummaryEventsAmt>538529</DirectExpenseSummaryEventsAmt>
        <NetIncomeSummaryAmt>-538529</NetIncomeSummaryAmt>
      </FundraisingEventInformationGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule G, Part II, Line 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>All events during FY20-21 were conducted virtually. Thus, all gross receipts are contributions.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleG>
    <IRS990ScheduleI documentId="IRS990ScheduleI">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Vermont State &amp; Agricultural College</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>85 S Prospect St</AddressLine1Txt>
          <CityNm>Burlington</CityNm>
          <StateAbbreviationCd>VT</StateAbbreviationCd>
          <ZIPCd>05405</ZIPCd>
        </USAddress>
        <RecipientEIN>030179440</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <PurposeOfGrantTxt>See Part IV</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Vanderbilt University Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3319 W End Ave</AddressLine1Txt>
          <CityNm>Nashville</CityNm>
          <StateAbbreviationCd>TN</StateAbbreviationCd>
          <ZIPCd>372036856</ZIPCd>
        </USAddress>
        <RecipientEIN>620476822</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <PurposeOfGrantTxt>See Part IV</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Pittsburgh</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3420 Forbes Ave</AddressLine1Txt>
          <CityNm>Pittsburgh</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>15260</ZIPCd>
        </USAddress>
        <RecipientEIN>250965591</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <PurposeOfGrantTxt>See Part IV</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of colorado Denver AMC and DC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>13001 E 17th Place</AddressLine1Txt>
          <CityNm>Aurora</CityNm>
          <StateAbbreviationCd>CO</StateAbbreviationCd>
          <ZIPCd>80045</ZIPCd>
        </USAddress>
        <RecipientEIN>846000555</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <PurposeOfGrantTxt>See Part IV</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Pittsburgh</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3420 Forbes Ave</AddressLine1Txt>
          <CityNm>Pittsburgh</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>15260</ZIPCd>
        </USAddress>
        <RecipientEIN>250965591</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <PurposeOfGrantTxt>See Part IV</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>5</Total501c3OrgCnt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part I, Line 2</FormAndLineReferenceDesc>
        <ExplanationTxt>For larger grants, the Organization requests semi-annual reports detailing the use of grant funds from the recipient organizations.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part II, Line 1(h) Purpose of Grant</FormAndLineReferenceDesc>
        <ExplanationTxt>1. THE UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE - PROJECT TITLE - COLLAGEN S-GLUTATHIONYLATION PROMOTES PULMONARY FIBROSIS THROUGH MYOFIBROBLAST ACTIVATION. HEALTHY HUMAN TISSUE IS DEVELOPED AND MAINTAINED BY TIGHTLY ORCHESTRATED INTERACTIONS BETWEEN CELLS AND THEIR ENVIRONMENT. ALTERATIONS IN THESE INTERACTIONS ARE KNOWN TO ACCOMMODATE OR LEAD TO DISEASE SUCH AS PULMONARY FIBROSIS. IN THE HUMAN LUNG, EPITHELIAL CELLS INTERACT WITH OTHER RESIDENT LUNG CELLS AND EXTRACELLULAR MATRIX TO PROPERLY PROVIDE A PROTECTIVE BARRIER OR SELECTIVE GAS EXCHANGE. HOWEVER, REPEATED DAMAGE TO THESE EPITHELIAL CELLS, WHETHER FROM GENETIC OR ENVIRONMENTAL ORIGINS, IS ASSOCIATED WITH THE DEVELOPMENT OF EXCESSIVE EXTRACELLULAR MATRIX (FIBROTIC SCARRING), ALTERED LUNG CELL IDENTITY AND IMPROPER INTERACTIONS BETWEEN CELLS. IN ADDITION TO THIS, OUR RESEARCH GROUP HAS DISCOVERED A LINK BETWEEN PULMONARY FIBROSIS AND ALTERED LUNG REDOX (REDUCTION/OXIDATION) STATES, SPECIFICALLY PROTEIN S-GLUTATHIONYLATION, PROVIDING A NEW WINDOW OF OPPORTUNITY FOR THERAPEUTIC INTERVENTION. THE RESEARCH GROUP IS THEREFORE STUDYING THE ROLES OF PROTEIN S-GLUTATHIONYLATION DURING THE PROCESSES OF EXCESSIVE EXTRACELLULAR MATRIX PRODUCTION, CELL DIFFERENTIATION AND CELL-TO-CELL COMMUNICATION IN THE LUNG, WITH THE GOAL OF RESOLVING FIBROTIC SCARRING AND ENABLING PROPER LUNG CELL FUNCTION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part II, Line 2(h) Purpose of Grant</FormAndLineReferenceDesc>
        <ExplanationTxt>2. VANDERBILT UNIVERSITY MEDICAL CENTER - PROJECT TITLE - YAP/WNT INTERACTIONS REGULATE EPITHELIAL CELL PROLIFERATION AND DIFFERENITATION LEADING TO ABNORMAL REPAIR AND PROGRESSION OF IPF THE LUNG HAS A REMARKABLE CAPACITY TO REGENERATE AFTER INJURY. HOWEVER, FAILURE OF THESE REPAIR MECHANISMS CONTRIBUTES TO DEVELOPMENT OF DISEASES INCLUDING IDIOPATHIC PULMONARY FIBROSIS (IPF), A CHRONIC FORM OF INTERSTITIAL LUNG DISEASE WITH POOR PROGNOSIS DUE TO IRREVERSIBLE PROGRESSIVE ALVEOLAR DAMAGE RESULTING IN RESPIRATORY FAILURE AND FATALITY USUALLY WITHIN 2-5 YEARS OF DIAGNOSIS. RECENT WORK DEMONSTRATED THE WNT SIGNALING PATHWAY IS INVOLVED DURING NORMAL LUNG REGENERATION AND IS UPREGULATED IN IPF. OUR PREVIOUS WORK IDENTIFIED THE HIPPO/YAP PATHWAY AS BEING ABNORMALLY ACTIVATED IN IPF EPITHELIAL CELLS, AND OUR PRELIMINARY DATA SHOWS ABNORMAL ACTIVATION OF YAP RESULTS IN ABNORMALLY DIFFERENTIATED RESPIRATORY CELLS. PRELIMINARY STUDIES PREDICT THAT YAP AND WNT MAY INTERACT TO REGULATE THE NORMAL AND DISEASE STATE CELLS. THIS PROJECT AIMS TO DETERMINE THE ROLES OF YAP ACTIVITY DURING NORMAL AND PATHOGENETIC REPAIR PROCESSES AND HOW YAP ACTIVITY MAY BE MODULATED BY WNT SIGNALING.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part II, Line 3(h) Purpose of Grant</FormAndLineReferenceDesc>
        <ExplanationTxt>3. UNIVERSITY OF PITTSBURGH - PROJECT TITLE - AIR POLLUTION: CLINICAL OUTCOMES AND EPIGENOMIC EFFECTS IN INTERSTITIAL LUNG DISEASES AIR POLLUTION IS A MASSIVE GLOBAL PUBLIC HEALTH PROBLEM, LEADING TO AN ESTIMATED 8.9 MILLION PREMATURE DEATHS WORLDWIDE ANNUALLY. PATIENTS WITH CHRONIC RESPIRATORY DISEASES ARE ESPECIALLY VULNERABLE TO THE HARMFUL EFFECTS OF AIR POLLUTION. OUR UNDERSTANDING OF THE IMPACTS OF AIR POLLUTION IN PATIENTS WITH FIBROTIC INTERSTITIAL LUNG DISEASE (ILD) IS LIMITED. FIBROTIC ILDS REPRESENT A GROUP OF OVER 200 DISEASES CHARACTERIZED BY SHORTNESS OF BREATH, LUNG FUNCTION DECLINE, AND HIGH MORBIDITY AND MORTALITY. THE BURDEN OF FIBROTIC ILDS IS INCREASING WORLDWIDE AS IS OUR UNDERSTANDING OF HOW ENVIRONMENTAL FACTORS CONTRIBUTE TO THE DEVELOPMENT AND PROGRESSION OF THESE CONDITIONS. THIS STUDY WILL UTILIZE CLINICAL DATA COLLECTED THROUGH THE PULMONARY FIBROSIS FOUNDATION (PFF) REGISTRY OF PATIENTS WITH FIBROTIC ILD TO CLARIFY HOW AIR POLLUTION IMPACTS CLINICAL OUTCOMES IN THESE PATIENTS AND THE MOLECULAR MECHANISMS WHICH UNDERLY THESE EFFECTS. ENVIRONMENTAL FACTORS MAY AFFECT DISEASE BY CONTROLLING HOW GENES RESULT IN PROTEIN PRODUCTION WITHOUT CHANGING THE GENETIC CODE (ALSO KNOWN AS EPIGENETICS). DNA METHYLATION IS ONE THE MOST COMMON EPIGENETIC CHANGES THAT CAN OCCUR DUE TO ENVIRONMENTAL EXPOSURES SUCH AS AIR POLLUTION. WE WILL FIRST LOOK AT HOW AIR POLLUTION AFFECTS LUNG FUNCTION, HOSPITAL ADMISSION, AND DEATH IN PATIENTS WITH ILD. SUBSEQUENTLY, WE WILL USE PATIENT BLOOD SAMPLES COLLECTED BY THE PFF TO EVALUATE DNA METHYLATION. OUR STUDY AIMS TO INCREASE UNDERSTANDING OF HOW ENVIRONMENTAL FACTORS CONTRIBUTE TO ILD DEVELOPMENT AND PROGRESSION. THIS STUDY MAY FIND NEW TOOLS FOR MONITORING AIR POLLUTION AND DISEASE PROGRESSION, ALONGSIDE NEW TARGETS FOR TREATMENT TO IMPROVE THE LIVES OF PATIENTS WITH ILD.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part II, Line 4(h) Purpose of Grant</FormAndLineReferenceDesc>
        <ExplanationTxt>4. UNIV OF COLORADO DENVER, AMC AND DC - PROJECT TITLE - IMPROVING PATIENT AND CAREGIVER OUTCOMES IN PULMONARY FIBROSIS: A NOVEL, DYADIC ASSESSMENT OF CAREGIVER BURDEN INDIVIDUALS WITH PULMONARY FIBROSIS (PF) LIVE WITH INTRUSIVE, BOTHERSOME SYMPTOMS AND IMPAIRED QUALITY OF LIFE. CAREGIVERS OF INDIVIDUALS WITH PF CAN EXPERIENCE SIGNIFICANT PHYSICAL, SOCIAL AND EMOTION IMPACTS IN THEIR OWN LIVES AS A RESULT OF CAREGIVING, A CONCEPT TERMED CAREGIVER BURDEN. CURRENTLY, WE DO NOT KNOW IF CAREGIVER BURDEN IS A SIGNIFICANT PROBLEM FOR CAREGIVERS OF INDIVIDUALS WITH PF. IF CAREGIVER BURDEN IS PRESENT, WE DO NOT KNOW WHAT FACTORS ABOUT PF CONTRIBUTE TO CAREGIVER BURDEN OR WHAT THE IMPACT OF BURDEN IS FOR BOTH CAREGIVERS AND PATIENTS. AS NEITHER PATIENTS NOR CAREGIVERS EXIST IN ISOLATION, THIS PROPOSAL WILL EVALUATE PATIENTS AND THEIR CAREGIVERS TOGETHER, CALLED DYADS, TO FURTHER OUR UNDERSTANDING OF CAREGIVER BURDEN IN PF. ULTIMATELY, OUR LONG-TERM GOAL IS TO UTILIZE THIS INFORMATION TO LESSEN CAREGIVER BURDEN AND IMPROVE OUTCOMES, INCLUDING QUALITY OF LIFE, FOR BOTH PATIENTS AND THEIR CAREGIVERS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part II, Line 5(h) Purpose of Grant</FormAndLineReferenceDesc>
        <ExplanationTxt>5. UNIVERSITY OF PITTSBURGH - PROJECT TITLE - INVESTIGATING THE MASTER REGULATORS OF MYOFIBROBLASTS IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE INTERSTITIAL LUNG DISEASE (ILD) IS THE LEADING CAUSE OF DEATH IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC), AN AUTOIMMUNE DISEASE RESULTING IN FIBROSIS OF THE SKIN, LUNGS, AND OTHER ORGANS. MYOFIBROBLASTS ARE THE KEY EFFECTOR CELL IN FIBROSIS DUE TO THEIR EXCESSIVE PRODUCTION OF COLLAGEN AND THEIR ACQUIRED CONTRACTILE CAPACITY; HOWEVER, NO TREATMENTS CURRENTLY EXIST TO TARGET THESE OVERACTIVE CELLS IN SSC-ILD OR OTHER ILDS. USING NOVEL TECHNOLOGY, WE ARE NOW ABLE TO ISOLATE INDIVIDUAL CELLS FROM THE LUNGS OF PATIENTS WITH SSC-ILD AT THE TIME OF LUNG TRANSPLANT AND STUDY THE RNA MOLECULES AND DNA STRUCTURE ENCODING FOR PROTEINS LIKE COLLAGEN, AS WELL AS ALL ACTIVE GENES IN THE CELL. UTILIZING THIS APPROACH, WE WILL DIRECTLY COMPARE THE RNA AND DNA STRUCTURE IN DISEASED MYOFIBROBLASTS WITH NORMAL FIBROBLASTS TO DETERMINE WHICH SPECIFIC TRANSCRIPTION FACTOR PROTEINS ARE OVERPRODUCED IN THE DISEASED FORM, THEN FURTHER EXAMINE THESE TRANSCRIPTION FACTORS AS POTENTIAL THERAPEUTIC TARGETS. THE DEVELOPMENT OF NEW MYOFIBROBLAST-DIRECTED THERAPIES HAS THE PROMISE OF PREVENTING DISEASE PROGRESSION TO RESPIRATORY FAILURE IN PATIENTS WITH SSC-ILD AND OTHER ILDS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="IRS990ScheduleJ">
      <HousingAllowanceOrResidenceInd>X</HousingAllowanceOrResidenceInd>
      <WrittenPolicyRefTAndEExpnssInd>false</WrittenPolicyRefTAndEExpnssInd>
      <SubstantiationRequiredInd>false</SubstantiationRequiredInd>
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <IndependentConsultantInd>X</IndependentConsultantInd>
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <WrittenEmploymentContractInd>X</WrittenEmploymentContractInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>false</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>false</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>false</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>false</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>false</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>false</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>false</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>false</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>false</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>William T Schmidt</PersonNm>
        <TitleTxt>Director/President and CEO</TitleTxt>
        <BaseCompensationFilingOrgAmt>282100</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>26000</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>2500</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>310600</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Scott Staszak</PersonNm>
        <TitleTxt>Chief Operating Officer</TitleTxt>
        <BaseCompensationFilingOrgAmt>212987</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>26000</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>0</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>238987</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Laura Sadler</PersonNm>
        <TitleTxt>Chief Marketing Officer</TitleTxt>
        <BaseCompensationFilingOrgAmt>185556</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>500</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>6794</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>192850</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Seth Klein</PersonNm>
        <TitleTxt>SENIOR VP, DEVELOPMENT</TitleTxt>
        <BaseCompensationFilingOrgAmt>153434</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>500</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>8336</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>4445</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>166715</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Kathryn TREBONSKY</PersonNm>
        <TitleTxt>VP, FINANCE THRU 04/01/21</TitleTxt>
        <BaseCompensationFilingOrgAmt>135389</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>500</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>9752</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>16896</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>162537</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule J, Part I, Line 1a</FormAndLineReferenceDesc>
        <ExplanationTxt>CEO RESIDES IN MD AND CANNOT RELOCATE AT THIS TIME, HOWEVER, HE NEEDS TO SPEND SUBSTANTIAL TIME IN CHICAGO AND THEREFORE PFF AGREED TO PROVIDE A HOUSING ALLOWANCE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule J, Part I, Line 1b</FormAndLineReferenceDesc>
        <ExplanationTxt>DETAILS ARE DISCLOSED IN CEO'S EMPLOYMENT CONTRACT. WE DO NOT OFFER THIS ARRANGEMENT TO OTHER STAFF MEMBERS AND THUS DO NOT HAVE A WRITTEN POLICY FOR A HOUSING ALLOWANCE. HOUSING ALLOWANCE ENDED DURING FY20-21.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleJ>
    <IRS990ScheduleO documentId="IRS990ScheduleO">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>CONTINUED FROM FORM 990, PART III, LINE 4A:</FormAndLineReferenceDesc>
        <ExplanationTxt>INDEPENDENTLY MANAGED BY A DATA COORDINATING CENTER. THE REGISTRY ALSO COLLECTS BIOLOGICAL SPECIMENS THAT PATIENTS HAVE AGREED TO GIVE, WHICH ARE DE-IDENTIFIED AND INDEPENDENTLY MANAGED BY A MEDICAL SPECIMEN STORAGE FACILITY ASSOCIATED WITH THE DATA COORDINATING CENTER. THE REGISTRY'S KEY AIMS ARE TO: (1) CONDUCT BENCHMARKING AND QUALITY IMPROVEMENT EFFORTS ACROSS THE PFF'S MEDICAL CENTER NETWORK; (2) DEVELOP A MORE REPRESENTATIVE UNDERSTANDING OF PF PATIENTS IN THE UNITED STATES; (3) FACILITATE RESEARCH IN IDENTIFIED PRIORITY AREAS; AND (4) INCREASE THE PFF'S REACH WITHIN THE PF COMMUNITY. AS OF JUNE 30, 2021, THE REGISTRY HAS ACTIVATED 42 SITES AND IDENTIFIED 2,003 PATIENTS FOR ENROLLMENT. THIS VITAL PROGRAM IS COMPLETING ITS FIRST PHASE AND WILL EMBARK ON THE NEXT PHASE TO CONTINUE TO CAPTURE CLINICAL PATIENT INFORMATION AND EXPAND INTO THE COMMUNITY TO COLLECT INFORMATION FROM OTHER PATIENTS, LUNG TRANSPLANT RECIPIENTS, CAREGIVERS, AND FAMILIES. THIS WILL PROVIDE A MORE REPRESENTATIVE UNDERSTANDING OF THE PF COMMUNITY AND CREATE A ROBUST POOL OF ENGAGED COMMUNITY MEMBERS FOR ADVOCACY, CLINICAL TRIALS, AND OTHER RESEARCH. TO LEARN MORE ABOUT THE PFF PATIENT REGISTRY, PLEASE GO TO: HTTPS://WWW.PULMONARYFIBROSIS.ORG/PFF-REGISTRY.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>CONTINUED FROM FORM 990, PART III, LINE 4B:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION DEVELOPED NEW EDUCATIONAL MATERIALS FOR PATIENTS WITH PF, THEIR CAREGIVERS, AND HEALTHCARE PROFESSIONALS IN FISCAL YEAR 2020-2021. THE PFF PRODUCED NEW PRINT MATERIALS IN ENGLISH AND SPANISH, INCLUDING THE "PREPARING FOR A LUNG TRANSPLANT" BOOKLET, THE "LIFE AFTER A LUNG TRANSPLANT" BOOKLET, AND THE "MEDICARE PATIENTS' OXYGEN RIGHTS" BROCHURE. THE PFF ALSO CREATED THE "RHEUMATOLOGY POCKET GUIDE" FOR HEALTHCARE PROVIDERS. ALL EDUCATIONAL DOCUMENTS ARE AVAILABLE AT PULMONARYFIBROSIS.ORG/ABOUT-US/WHAT-WE-DO/EDUCATION. THE PFF WORKED WITH THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND RESPIRATORY CARE TO CREATE A PULMONARY REHABILITATION TOOLKIT FOR PATIENTS. THE PULMONARY REHABILITATION TOOLKIT INCLUDES A SERIES OF EXERCISE VIDEOS, WORKSHEETS, AND INFORMATIONAL WEBINARS. THE PFF RELEASED SHORT VIDEOS AS PART OF A "MYTHS &amp; MISCONCEPTIONS" SERIES. MISCONCEPTIONS INCLUDED TOPICS LIKE "NO ONE KNOWS WHAT CAUSES PULMONARY FIBROSIS"I HEARD OXYGEN IS ADDICTIVE &amp; WILL WEAKEN MY LUNGS." THE PFF ALSO RELEASED SHORT VIDEOS HIGHLIGHTING TOP 5 PIECES OF INFORMATION FOR PF PATIENTS. THE PFF RELEASED A SUITE OF MATERIALS TO HELP PATIENTS NAVIGATE TELEMEDICINE, INCLUDING WEBINARS IN ENGLISH AND SPANISH, A TELEMEDICINE CHECKLIST FOR PF PATIENTS, A BOOKLET ON TELEMEDICINE FOR PF PATIENTS, AND A SURVEY OF PATIENTS' EXPERIENCE WITH TELEMEDICINE. IN FEBRUARY 2021, THE PFF CHANGED THE NAME OF THE PATIENT COMMUNICATION CENTER TO THE PFF HELP CENTER. THIS NAME REFLECTS THE BROAD RANGE OF INFORMATION AND RESOURCES THAT THE PFF HELP CENTER PROVIDES TO MEMBERS OF THE PF COMMUNITY. THE PFF WEBINAR SERIES ENGAGES THE PF COMMUNITY IN AN ONLINE WEBINAR DISCUSSION WHERE THEY LEARN FROM, CONNECT WITH, AND POSE QUESTIONS TO LEADING PULMONARY FIBROSIS SPECIALISTS. NINE WEBINARS WERE PRESENTED IN FISCAL YEAR 2020-21 AND ALL CAN BE VIEWED ON THE PFF WEBSITE AT HTTPS://BIT.LY/PFFWEBINARS AND ON THE FOUNDATION'S YOUTUBE CHANNEL. TOPICS ADDRESSED DURING THIS TIME PERIOD INCLUDE THE BENEFITS OF DIVERSITY IN RESEARCH, COVID-19, SYMPTOM MANAGEMENT, AND ACUTE EXACERBATIONS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>CONTINUED FROM FORM 990, PART III, LINE 4C:</FormAndLineReferenceDesc>
        <ExplanationTxt>AND HEALTHCARE PROVIDERS TO SPOT SYMPTOMS EARLY FOR MORE ACCURATE, TIMELY DIAGNOSES. WE SHARPENED OUR MESSAGING FROM SIMPLY "KNOW THE SYMPTOMS" TO "EARLIER DIAGNOSIS." THE CAMPAIGN ROLLED OUT WITH A PRESS RELEASE AND REDESIGNED DIGITAL AND PRINT ADS DIRECTING AUDIENCES TO ABOUTPF.ORG.WE ALSO LAUNCHED A NEW SITE, ABOUTPF.ORG/ESPAOL, FOR MEMBERS OF THE HISPANIC POPULATION WHO MAY BE AT RISK FOR PF. OUR MEDIA RELATIONS EFFORT PRODUCED FEATURE STORIES ON RELEVANT TOPICS THROUGHOUT THE YEAR. WE KEPT PFF EXPERTS TOP-OF-MIND WITH TRADE MEDIA WITH CONTINUAL UPDATES ON TOPICS INCLUDING THE FIRST PATIENT ENROLLED IN PRECISION, PFF SCHOLARS PROGRAM, COVID-19 VACCINE STATEMENT, NEW PFF WEBSITE, AND MORE. PFF AMBASSADOR STORIES WERE HIGHLIGHTED IN NATIONWIDE MEDIA THROUGH COVERAGE ABOUT HILL DAY, PFF WALKS, AND TEAM PFF EVENTS. DURING PF AWARENESS MONTH, DR. SONYE DANOFF PARTICIPATED IN A HIGH-IMPACT RADIO MEDIA TOUR WHERE SHE DESCRIBED THE SYMPTOMS AND RISK FACTORS FOR PF. ENGLISH AND SPANISH DIGITAL ADS DROVE TRAFFIC TO THE ABOUTPF.ORG MICROSITES. PULMONARY FIBROSIS AWARENESS MONTH (SEPTEMBER) IS WHEN THE PF COMMUNITY UNITES AS A COLLECTIVE VOICE TO ENHANCE DISEASE AWARENESS AND PROVIDE OUTREACH TO THOSE IN NEED. DURING PULMONARY FIBROSIS AWARENESS MONTH, THE PF COMMUNITY JOINED THE PFF AND PARTICIPATED IN THE #BLUEUP4PF CAMPAIGN, ATTENDED VIRTUAL EDUCATIONAL AND TEAM PFF EVENTS, PARTICIPATED IN WEBINARS, AND SPREAD DISEASE AWARENESS THROUGH SOCIAL MEDIA. ALTHOUGH 2020 PRESENTED A PARTICULARLY DIFFICULT MEDIA ENVIRONMENT WITH HEALTH COVERAGE FOCUSED ON THE COVID-19 PANDEMIC, THESE ACTIVITIES OVERALL CONTINUED TO INCREASE AWARENESS OF PF AND ITS RISK FACTORS NATIONWIDE, GENERATING MORE THAN 370.2 MILLION IMPRESSIONS, AND SUCCESSFULLY GREW TRAFFIC TO THE ABOUTPF.ORG MICROSITES AND TO THE PFF'S WEBSITE, PULMONARYFIBROISIS.ORG. THE CAMPAIGN DROVE INQUIRIES TO THE PFF HELP CENTER. CONSTITUENCIES SERVED BY THE MARKETING CAMPAIGN INCLUDED PATIENTS AND POTENTIAL PATIENTS; CAREGIVERS AND FAMILIES; HEALTHCARE PROVIDERS; AND AT-RISK POPULATIONS. FOR MORE INFORMATION VISIT PULMONARYFIBROSIS.ORG/ABOUT-US/WHAT-WE-DO/PATIENT-SUPPORT-PROGRAMS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART III, LINE 4D:</FormAndLineReferenceDesc>
        <ExplanationTxt>1. PFF CARE CENTER NETWORK: THE PULMONARY FIBROSIS FOUNDATION (PFF) IS DEDICATED TO PROMOTING EARLIER RECOGNITION AND DIAGNOSIS OF PULMONARY FIBROSIS AND ENSURING THAT PATIENTS RECEIVE THE HIGHEST QUALITY HEALTHCARE. AS PART OF THAT COMMITMENT, SINCE 2013 THE PFF HAS WORKED WITH THE PF MEDICAL COMMUNITY TO ESTABLISH AND EXPAND THE PFF CARE CENTER NETWORK (CCN) TO 68 CARE CENTERS WHERE PEOPLE WITH PF CAN FIND EXPERIENCED MEDICAL PROFESSIONALS WHO UNDERSTAND THEIR DISEASE AND SUPPORT SERVICES TO IMPROVE THE QUALITY OF THEIR LIVES. THE GOALS OF THE PFF CCN IS TO DELIVER STATE OF THE ART, PATIENT-CENTERED CARE; TO DISSEMINATE EDUCATION TO SUPPORT OUR PATIENTS, CAREGIVERS AND PROVIDERS; TO GIVE VOICE TO THE NEEDS OF OUR COMMUNITY THROUGH ADVOCACY AND FUNDRAISING; AND TO ACCELERATE RESEARCH IN PF BOTH DIRECTLY AND THROUGH COLLABORATIONS AND NETWORKING. 2. RESEARCH: THE PULMONARY FIBROSIS FOUNDATION (PFF) PLACES ENORMOUS IMPORTANCE ON CREATING AN ENVIRONMENT THAT WILL ASSIST IN THE DEVELOPMENT OF EFFECTIVE TREATMENTS FOR PULMONARY FIBROSIS (PF). IN ADDITION TO CREATING THE PFF PATIENT REGISTRY TO PROVIDE RESEARCHERS WITH DATA TO ADDRESS SPECIFIC RESEARCH QUESTIONS, WE ARE DIRECTLY FUNDING PF RESEARCH THROUGH THE PFF SCHOLARS PROGRAM, DEVELOPING LEGISLATIVE ADVOCACY EFFORTS, ENCOURAGING COLLABORATIVE RELATIONS BETWEEN INDUSTRY AND ACADEMIC RESEARCHERS, DELIVERING KEY COMMUNICATIONS TO PATIENTS, AND DEVELOPING SOLUTIONS TO BRIDGE EXISTING GAPS IN PF RESEARCH. THE PFF SCHOLARS PROGRAM SUPPORTS PROJECTS THAT OFFER A HIGH LIKELIHOOD OF IMPROVING THE UNDERSTANDING OF PF IN THE FOLLOWING RESEARCH AREAS: BASIC SCIENCE, TRANSLATIONAL, CLINICAL, EPIDEMIOLOGICAL, AND HEALTH SERVICES. THE GOAL OF THE PFF SCHOLARS PROGRAM IS TO SUPPORT EMERGING INVESTIGATORS TO ADVANCE RESEARCH THAT COULD TRANSLATE INTO SUCCESSFUL THERAPIES, WHILE ALSO ENABLING THESE PROMISING RESEARCHERS TO OBTAIN INDEPENDENT FUNDING AND CONTINUE THEIR CUTTING-EDGE RESEARCH. THE RESEARCH REVIEW COMMITTEE ADMINISTERS THE PEER-REVIEW PROCESS, WHICH IS COMPRISED OF 25 CREDIBLE EXPERTS FROM THE US AND CANADA. AFTER THEIR REVIEW AND RECOMMENDATIONS, THE PFF FUNDED SIX $50,000 GRANTS OVER A TWO YEAR PERIOD IN THE 2020 CYCLE. THE PFF ALSO CONSIDERS OTHER SMALLER GRANTS THAT FIT THE RESEARCH GUIDELINES. 3. OUTREACH AND AWARENESS: THE PFF AMBASSADOR PROGRAM EMPOWERS PATIENTS, CAREGIVERS, AND HEALTH CARE PROFESSIONALS AS SPOKESPERSONS FOR THE PF COMMUNITY ON BEHALF OF THE PFF. PFF AMBASSADORS PROMOTE DISEASE AWARENESS, PROVIDE UP-TO-DATE INFORMATION, AND OFFER HOPE AND INSPIRATION TO THOSE AFFECTED BY PULMONARY FIBROSIS. PFF AMBASSADORS ARE AVAILABLE TO SPEAK AT PFF CARE CENTER NETWORK EVENTS, SUPPORT GROUP MEETINGS, FUNDRAISING EVENTS, AND OTHER DISEASE AWARENESS AND EDUCATION PROGRAMS. PFF AMBASSADORS INCLUDE PATIENTS, CAREGIVERS, LUNG TRANSPLANT RECIPIENTS, AND FAMILY MEMBERS. IN NOVEMBER 2020, THE PFF HOSTED AN ONLINE VIRTUAL VOLUNTEER MEETING FOR VOLUNTEERS, INCLUDING PFF AMBASSADORS. THE PFF PROVIDES ONGOING TRAINING TO SUPPORT GROUP LEADERS THROUGHOUT THE YEAR. PULMONARY FIBROSIS AWARENESS MONTH (SEPTEMBER) IS WHEN THE PF COMMUNITY UNITES AS A COLLECTIVE VOICE TO ENHANCE DISEASE AWARENESS AND PROVIDE OUTREACH TO THOSE IN NEED. DURING PULMONARY FIBROSIS AWARENESS MONTH, THE PF COMMUNITY JOINED THE PFF AND PARTICIPATED IN THE #BLUEUP4PF CAMPAIGN, ATTENDED EDUCATIONAL EVENTS, HOSTED TEAM PFF FUNDRAISING EVENTS, PARTICIPATED IN WEBINARS AND SPREAD DISEASE AWARENESS THROUGH SOCIAL MEDIA. THE FOLLOWING PROGRAMMATIC SERVICE ACCOMPLISHMENTS ARE HIGHLIGHTED BELOW. THE PFF MEDICAL TEAM HAS DEVELOPED A NEW PFF CCN ANNUAL REPORT TO ALL 68 CARE CENTERS. THIS CENTER BASED REPORT WILL HAVE A STRONG EMPHASIS ON BENCHMARKING, RESEARCH, CLINICAL CARE, COMMUNITY-BASED CLINICAL SUPPORT, AND PATIENT SATISFACTION. WE ANTICIPATE THAT WITH THIS DATA CENTRIC APPROACH WE WILL BE BETTER POSITIONED TO UNDERSTAND THE UNIQUE CHARACTERISTICS WITHIN OUR NETWORK. THE PALLIATIVE CARE SERVICES IN CARE CENTERS SURVEY WORKING GROUP STRIVED FOR 100% CARE CENTER PARTICIPATION WITH AN ESTIMATED 136 SURVEY RESPONSES. THE AIMS OF THIS SURVEY IS TO UNDERSTAND THE ROLE OF PALLIATIVE CARE SERVICES, PERSPECTIVES AND CURRENT RESOURCES AVAILABLE TO PROVIDERS WHO CARE FOR PATIENTS WITH PULMONARY FIBROSIS AND INTERSTITIAL LUNG DISEASE. THE SURVEY WAS DISSEMINATED TO PHYSICIANS, ADVANCE PRACTICE PROVIDERS, NURSES, RESPIRATORY THERAPISTS, AND SOCIAL WORKERS WHO CARE FOR ILD PATIENTS AT THE 68 PFF CARE CENTERS. INTERSTITIAL LUNG DISEASE (ILD) CAUSES A PROFOUND SYMPTOM BURDEN AND CARRIES A HIGH MORTALITY. PALLIATIVE CARE IS DEDICATED TO IMPROVING QUALITY OF LIFE AND EMPOWERING PATIENTS IN ADVANCE CARE PLANNING. EARLY INTEGRATION OF PALLIATIVE CARE IN ILD IMPROVES THE RATES OF ADVANCE CARE PLANNING AND SYMPTOMATIC MANAGEMENT. KNOWLEDGE OF ILD PROVIDER PERSPECTIVES ON PALLIATIVE CARE IS KEY TO IMPROVING CARE DELIVERY TO ILD PATIENTS. DESCRIPTIVE STATISTICS WERE COMPILED FOR SURVEY RESPONSES FROM OCTOBER-DECEMBER 2020. THE SURVEY FOR PFF CARE CENTERS DURING THE 2020 COVID-19 PANDEMIC WAS CONDUCTED BY THE PFF CARE CENTER NETWORK. THE PURPOSE OF THIS SURVEY IS TO GATHER CENTER BASED INFORMATION ON THE IMPACT OF THE CORONAVIRUS DISEASE (COVID-19) BY DEVELOPING FUNCTIONING STRATEGIES FOR CLINICAL TRIAL NETWORKS IN THE EVENT OF THE NEXT SURGE OR OTHER EVENT MAKING PHYSICAL VISITS NOT POSSIBLE. THE RESULTS FROM THIS SURVEY WILL ONLY BE USED FOR ACADEMIC RESEARCH IN ORDER TO ALLOW THE PFF TO MOVE HEALTH INITIATIVES AND ADVOCACY RECOMMENDATIONS MEASURES FORWARD. WE UNDERSTAND THAT WE STILL HAVE MUCH WORK TO BE DONE, BUT WITH KEY RESEARCH INITIATIVES SUCH AS THESE WE WILL MAKE AN IMPACT IN PROMOTING EARLIER RECOGNITION AND DIAGNOSIS OF PULMONARY FIBROSIS AND ENSURING THAT PATIENTS RECEIVE THE HIGHEST QUALITY HEALTHCARE. 4. ADVOCACY: THE PFF ENGAGED POLICYMAKERS IN ADVOCATING FOR INCREASED FUNDING FOR PULMONARY FIBROSIS RESEARCH AND IMPROVED ACCESS TO OXYGEN FOR PATIENTS. THE PFF HOSTED A VIRTUAL HILL DAY IN MARCH TO ALLOW CONSTITUENTS TO SPEAK WITH THEIR MEMBERS OF CONGRESS ABOUT THE IMPACT OF PULMONARY FIBROSIS IN THEIR LIVES AND THE NEED FOR RESEARCH FUNDING. CONGRESS INCLUDED LANGUAGE ABOUT THE NEED FOR PULMONARY FIBROSIS RESEARCH IN THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE APPROPRIATIONS REPORT AND MAINTAINED PF AS AN ELIGIBLE TOPIC IN THE PEER REVIEWED MEDICAL RESEARCH PROGRAM. THE PFF ALSO JOINED OTHER PATIENT ADVOCACY AND PROFESSIONAL ORGANIZATIONS IN ADVOCATING FOR IMPROVED ACCESS TO PULMONARY REHABILITATION. THE CENTERS FOR MEDICARE &amp; MEDICAID SERVICES INTRODUCED A FLEXIBILITY TO ALLOW FOR REIMBURSEMENT OF PULMONARY REHABILITATION VIA TELEHEALTH DURING THE COVID-19 PUBLIC HEALTH EMERGENCY.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>5. PFF: PATIENT COMMUNICATION CENTER (PCC):</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PFF PATIENT COMMUNICATION CENTER (PCC) SERVES AS THE CENTRAL INFORMATION HUB FOR PULMONARY FIBROSIS PATIENTS, CAREGIVERS, THE SUPPORT GROUP LEADER NETWORK (SEE SUPPORT GROUP SECTION), AND HEALTH CARE PROFESSIONALS. THE PCC STAFF PROVIDES GENERAL INFORMATION ABOUT PULMONARY FIBROSIS THAT IS TAILORED TO INDIVIDUALS' NEEDS AND ANSWERS QUESTIONS ABOUT THE AVAILABILITY OF SUPPORT SERVICES AND OTHER ESSENTIAL RESOURCES. RESOURCES AVAILABLE INCLUDE: INFORMATION ON PFF PROGRAMS, EDUCATIONAL AND ADVOCACY MATERIALS, HOW TO FIND MEDICAL CARE AND SUPPORT GROUPS, ACCESS TO SUPPORT SERVICES, INFORMATION ABOUT AVAILABLE TREATMENTS, AND HOW TO FIND CLINICAL TRIALS. THE FOUNDATION CONTINUOUSLY SURVEYS THE PF COMMUNITY TO DETERMINE ADDITIONAL EDUCATIONAL MATERIALS OR TRANSLATIONS OF CURRENT MATERIALS THAT ARE NEEDED AND WORKS TO DEVELOP THOSE MATERIALS TO FIT UNMET NEEDS IN THE COMMUNITY. THE FOUNDATION ALSO FACILITATES PHYSICIAN EDUCATION BY PROVIDING MATERIALS THROUGH THE PATIENT COMMUNICATION CENTER AND AT EDUCATIONAL CONFERENCES. THE FOUNDATION MAINTAINS AN OXYGEN INFORMATION LINE TO PROVIDE PATIENTS AND CAREGIVERS WITH GENERAL INFORMATION ON ACCESSING AND SAFELY USING SUPPLEMENTAL OXYGEN. IN FISCAL YEAR 2019-2020, THE PATIENT COMMUNICATION CENTER RECEIVED 4,647 INQUIRIES VIA TELEPHONE AND EMAIL. 6. PFF SUMMIT: PFF SUMMIT 2021 IS THE PFF'S BIENNIAL INTERNATIONAL HEALTH CARE CONFERENCE ON PULMONARY FIBROSIS (PF). THE GOAL OF THE PFF SUMMIT IS TO FOSTER A COLLABORATIVE ENVIRONMENT TO IMPROVE EDUCATION AND AWARENESS OF PF AND TO IDENTIFY NEW APPROACHES TO TREAT, AND ULTIMATELY CURE, THIS DEVASTATING DISEASE. THE PFF SUMMIT FEATURES AN INNOVATIVE CONTINUING MEDICAL EDUCATION (CME) PROGRAM FOR HEALTH CARE PROFESSIONALS AND SESSIONS FOR PF PATIENTS AND CAREGIVERS THAT ADDRESS THEIR GROWING EDUCATIONAL NEEDS. (NOTE: SOME EXPENSES FOR THE PFF SUMMIT 2021 WERE INCLUDED IN THE 2019 FORM 990). 7. SUPPORT GROUPS: THE PFF SUPPORT GROUP LEADER NETWORK PROVIDES A FORUM FOR PF SUPPORT GROUP LEADERS TO CONNECT, EXCHANGE IDEAS, AND SHARE BEST PRACTICES. THE PFF'S SUPPORT GROUP NETWORK CONSISTS OF OVER 140 SUPPORT GROUPS ACROSS THE COUNTRY. THE PFF PROVIDES AN ONLINE PLATFORM FOR GROUPS TO USE TO MEET SAFELY DURING COVID-19. THE PFF PROVIDES PHONE-BASED SUPPORT GROUPS TO PATIENTS AND CAREGIVERS WHO DO NOT HAVE A LOCAL SUPPORT GROUP OR WOULD LIKE EXTRA SUPPORT. IN FISCAL YEAR 2020-21, THE PFF ADDED TWO NEW GROUPS (A GROUP FOR SPANISH SPEAKERS AND A GROUP FOR LUNG TRANSPLANT RECIPIENTS). THE PFF NOW HAS A TOTAL OF FOUR PHONE-BASED SUPPORT GROUPS. VISIT HTTP://BIT.LY/PFFSUPPORT TO LEARN MORE. IN NOVEMBER 2020, THE PFF HOSTED AN ONLINE VIRTUAL VOLUNTEER MEETING FOR VOLUNTEERS, INCLUDING SUPPORT GROUP LEADERS. THE PFF PROVIDES ONGOING TRAINING TO SUPPORT GROUP LEADERS THROUGHOUT THE YEAR AND THE COUNTRY. THE PFF PROVIDES AN ONLINE PLATFORM FOR GROUPS TO USE TO MEET SAFELY DURING COVID-19. THE PFF PROVIDES PHONE-BASED SUPPORT GROUPS TO PATIENTS AND CAREGIVERS WHO DO NOT HAVE A LOCAL SUPPORT GROUP OR WOULD LIKE EXTRA SUPPORT. IN FISCAL YEAR 2020-21, THE PFF ADDED TWO NEW GROUPS (A GROUP FOR SPANISH SPEAKERS AND A GROUP FOR LUNG TRANSPLANT RECIPIENTS). THE PFF NOW HAS A TOTAL OF FOUR PHONE-BASED SUPPORT GROUPS. VISIT HTTP://BIT.LY/PFFSUPPORT TO LEARN MORE. IN NOVEMBER 2020, THE PFF HOSTED AN ONLINE VIRTUAL VOLUNTEER MEETING FOR VOLUNTEERS, INCLUDING SUPPORT GROUP LEADERS. THE PFF PROVIDES ONGOING TRAINING TO SUPPORT GROUP LEADERS THROUGHOUT THE YEAR. FORM 990, PART VI, SECTION B, LINE 11B: A COPY OF FORM 990 IS REVIEWED BY THE FINANCE COMMITTEE BEFORE FILING. THE FORM 990 IS AVAILABLE TO ALL BOARD MEMBERS BEFORE FILING THE FORM.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION HAS A CONFLICT OF INTEREST POLICY WITHIN THE EMPLOYEE HANDBOOK AND ALL EMPLOYEES ARE REQUIRED TO ADHERE TO THE POLICY. EMPLOYEES SIGN A DISCLOSURE FORM EACH YEAR. ANNUALLY, BOARD MEMBERS ARE SENT A FORM TO FILL OUT STATING WHETHER THEY HAVE ANY CONFLICTS OF INTEREST. IF SUCH CONFLICTS EXIST, THEN THEY FILL OUT AN ADDITIONAL FORM OUTLINING THOSE CONFLICTS. THE EXECUTIVE COMMITTEE REVIEWS ANY CONFLICTS THAT ARISE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINES 15A &amp; B:</FormAndLineReferenceDesc>
        <ExplanationTxt>CHIEF EXECUTIVE OFFICER AND CHIEF OPERATING OFFICER'S COMPENSATION WAS APPROVED BY THE EXECUTIVE COMMITTEE, WHICH SERVES AS THE COMPENSATION COMMITTEE. THIS APPROVAL WAS BASED ON A REVIEW BY AN INDEPENDENT COMPENSATION CONSULTANT AND IS SUPPORTED BY A WRITTEN EMPLOYMENT CONTRACT. THE COMMITTEE ALSO REVIEWED COMPENSATION SURVEYS AND FORM 990S OF OTHER ORGANIZATIONS TO ENSURE THE COMPENSATION WAS APPROPRIATE. THE SALARY FOR THE CHIEF MARKETING OFFICER WAS NOT REVIEWED BY THE COMPENSATION COMMITTEE, BUT THE SALARY WAS IN LINE WITH THE MARKET.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION MAKES ITS FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST AND ON THE ORGANIZATION'S WEBSITE. THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY AVAILABLE TO THE PUBLIC.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:SITE PAYMENTS TOTAL FEES:747519</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:REGISTRY DCC CONSULTING TOTAL FEES:488144</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:OTHER CONSULTATION TOTAL FEES:438857</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:REGISTRY CONSULTING TOTAL FEES:259615</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:MARKETING CAMPAIGN CONSULTING TOTAL FEES:230532</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:MARKETING CONSULTING TOTAL FEES:217999</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:MEDICAL CONSULTING TOTAL FEES:186951</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:RECRUITMENT FEES TOTAL FEES:90424</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:OTHER OUTSIDE SERVICES TOTAL FEES:50532</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:TRANSLATION SERVICES TOTAL FEES:41542</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:MERCHANT CARD CHARGES TOTAL FEES:35928</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:REGISTRY HRCT CONSULTING TOTAL FEES:29641</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:WRITING/EDITING TOTAL FEES:27850</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:GRAPHIC DESIGN TOTAL FEES:25650</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:MEDIA RELATIONS TOTAL FEES:14414</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:EMPLOYEE ADMINISTRATION FEES TOTAL FEES:13988</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:STIPENDS TOTAL FEES:8150</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:IT CONSULTING TOTAL FEES:6137</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:CME TOTAL FEES:4500</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 PART IX LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION:PHOTOGRAPHY TOTAL FEES:1642</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
